These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35614270)

  • 21. CDKN2A-p16 Deletion and Activated KRAS
    Sun J; Sepulveda JL; Komissarova EV; Hills C; Seckar TD; LeFevre NM; Simonyan H; Young C; Su G; Del Portillo A; Wang TC; Sepulveda AR
    Cell Mol Gastroenterol Hepatol; 2024; 17(5):769-784. PubMed ID: 38296052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.
    Murray L; Sedo A; Scott M; McManus D; Sloan JM; Hardie LJ; Forman D; Wild CP
    Gut; 2006 Oct; 55(10):1390-7. PubMed ID: 16682429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
    Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
    Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
    J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Esophageal adenocarcinoma arising in cervical inlet patch with synchronous Barrett's esophagus-related dysplasia.
    Tanaka M; Ushiku T; Ikemura M; Shibahara J; Seto Y; Fukayama M
    Pathol Int; 2014 Aug; 64(8):397-401. PubMed ID: 25143128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Qualitative mapping of Barrett's metaplasia: a prerequisite for intervention trials.
    Eisen GM; Montgomery EA; Azumi N; Hartmann DP; Bhargava P; Lippman M; Benjamin SB
    Gastrointest Endosc; 1999 Dec; 50(6):814-8. PubMed ID: 10570342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.
    Ross-Innes CS; Chettouh H; Achilleos A; Galeano-Dalmau N; Debiram-Beecham I; MacRae S; Fessas P; Walker E; Varghese S; Evan T; Lao-Sirieix PS; O'Donovan M; Malhotra S; Novelli M; Disep B; Kaye PV; Lovat LB; Haidry R; Griffin M; Ragunath K; Bhandari P; Haycock A; Morris D; Attwood S; Dhar A; Rees C; Rutter MD; Ostler R; Aigret B; Sasieni PD; Fitzgerald RC;
    Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):23-31. PubMed ID: 28404010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia.
    Kunzmann AT; Thrift AP; Johnston BT; McManus DT; Gavin AT; Turkington RC; Coleman HG
    Aliment Pharmacol Ther; 2019 May; 49(10):1274-1281. PubMed ID: 30950101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
    Trakál E; Guidi A; Butti AL; Trakál JJ; Sambuelli R; Zárate FE
    Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunohistochemical expression of the p53 and Ki-67 proteins in Barrett's esophagus in Korea].
    Kim CW; Lee BI; Kim BW; Kim JI; Park SH; Kim JK; Han SW; Jung IS; Sun HS; Lee AW; Lee KY
    Korean J Gastroenterol; 2005 Sep; 46(3):189-95. PubMed ID: 16179838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
    Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
    Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
    Sharma P; Shaheen NJ; Katzka D; Bergman JJGHM
    Gastroenterology; 2020 Feb; 158(3):760-769. PubMed ID: 31730766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
    Wani S; Rubenstein JH; Vieth M; Bergman J
    Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
    Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma.
    Moore JH; Lesser EJ; Erdody DH; Natale RB; Orringer MB; Beer DG
    Int J Cancer; 1994 Feb; 56(4):487-93. PubMed ID: 7906678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barrett's esophagus: a surgical disease.
    Patti MG; Arcerito M; Feo CV; Worth S; De Pinto M; Gibbs VC; Gantert W; Tyrrell D; Ferrell LF; Way LW
    J Gastrointest Surg; 1999; 3(4):397-403; discussion 403-4. PubMed ID: 10482692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-goblet cell population of Barrett's esophagus: an immunohistochemical demonstration of intestinal differentiation.
    Chaves P; Cardoso P; de Almeida JC; Pereira AD; Leitao CN; Soares J
    Hum Pathol; 1999 Nov; 30(11):1291-5. PubMed ID: 10571507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.